Drugs / TSA-T
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06193759 | Sep 2024 → Dec 2030 expected | atypical teratoid rhabdoid tumor, childhood central nervous system primitive neuroectodermal neoplasm, childhood medulloblastoma, embryonal tumor with multilayered rosettes +2 | Children's National Research Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSA-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06193759 ↗ |
| Action | Deplete | “multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA)” NCT06193759 ↗ |
| Modality | Cell therapy | “multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T)” NCT06193759 ↗ |
| Route | Other | “All infusions will be intracerebroventricularly (ICV) administered through the protocol-required Rickham reservoir.” NCT06193759 ↗ |